Abstract
The matricellular protein connective tissue growth factor (CTGF, CCN2) is overexpressed in several forms of cancer and may represent a novel target in anti-cancer therapy. However, whether CCN2 is expressed in melanoma cells is unknown. The highly metastatic murine melanoma cell line B16(F10) was used for our studies. Real time polymerase chain reaction analysis was used to detect mRNA expression of CCN1, CCN2, CCN3 and CCN4 in Western blot and immunofluorescence analyses were used to detect CCN2 protein. Inhibitors of signal transduction cascades were used to probe the mechanism underlying CCN2 expression in B16(F10) cells. CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells. Expression of CCN1, CCN3 and CCN4 was not reduced by PP2 or U0126; in fact, expression of CCN4 mRNA was elevated by PP2 or U0126 treatment. To our surprise, CCN2 protein was detected in the nuclei of B16(F10) cells, and was undetectable in the cytoplasm. CCN2 was expressed in B16(F10) melanoma cells, adding to the list of cancer cells in which CCN2 is expressed. Of the CCN family members tested, only CCN2 is downstream of the highly oncogenic MEK/ERK pathway. CCN2 should be further evaluated for a possible role in melanoma growth and progression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M (2006) Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 5:1108–1116
Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16(3):368–377, Epub 2008 Oct 10
Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Feazell J, Yang GP, Koong A, Giaccia AJ (2009) The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 69(3):775–784
Bleau AM, Planque N, Perbal B (2005) CCN proteins and cancer: two to tango. Front Biosci 10:998–1009
Chen CC, Lau LF (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41(4):771–783
Chen Y, Segarini P, Raoufi F, Bradham D, Leask A (2001) Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome. Exp Cell Res 271(1):109–117
Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20:2149–2182
Dobroff AS, Wang H, Melnikova VO, Villares GJ, Zigler M, Huang L, Bar-Eli M (2009) Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem 284(38):26194–26206
Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, Wong C, Kaper F, Sutphin P, Nacamuli R, Hockel M, Le Q, Longaker M, Yang G, Koong A, Giaccia A (2006) Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 66:5816–5827
Eguchi T, Kubota S, Kawata K, Mukudai Y, Ohgawara T, Miyazono K, Nakao K, Kondo S, Takigawa M (2007) Different transcriptional strategies for ccn2/ctgf gene induction between human chondrocytic and breast cancer cell lines. Biochimie 89(3):278–288, Epub 2007 Jan 3
Flaherty KT, Hodi FS, Bastian BC (2010) Mutation-driven drug development in melanoma. Curr Opin Oncol 22(3):178–183
Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B, Herlyn M (2008) Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27(18):2552–2560
Hartel M, Di Mola FF, Gardini A, Zimmermann A, Di Sebastiano P, Guweidhi A, Innocenti P, Giese T, Giese N, Büchler MW, Friess H (2004) Desmoplastic reaction influences pancreatic cancer growth behavior. World J Surg 28(8):818–825, Epub 2004 Aug 3
Kim LC, Song L, Haura EB (2009) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6(10):587–595
Kondo S, Kubota S, Mukudai Y, Moritani N, Nishida T, Matsushita H, Matsumoto S, Sugahara T, Takigawa M (2006) Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3’-untranslated region interacting with a cellular protein in human chondrosarcoma cells. Oncogene 25(7):1099–1110
Kubo M, Kikuchi K, Nashiro K, Kakinuma T, Hayashi N, Nanko H, Tamaki K (1998) Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br J Dermatol 139(2):192–197
Leask A (2009) Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal 3(2):161–162, Epub 2009 May 29
Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803–4810
Leask A, Holmes A, Black CM, Abraham DJ (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278:13008–13015
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25(4):402–408
Mao Z, Ma X, Rong Y, Cui L, Wang X, Wu W, Zhang J, Jin D (2010) Connective tissue growth factor enhances the migration of gastric cancer through downregulation of E-cadherin via the NF-κB pathway. Cancer Sci. doi:10.1111/j.1349-7006.2010.01746.x
McCallum L, Lu W, Price S, Lazar N, Perbal B, Irvine AE (2009) CCN3: a key growth regulator in chronic myeloid leukaemia. J Cell Commun Signal 3(2):115–124
Namkoong J, Martino JJ, Chen S (2006) From existing therapies to novel targets: a current view on melanoma. Front Biosci 11:2081–2092
Perbal B (1999) Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression. Mol Pathol 52(2):84–91
Perbal B (2001) NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 54:57–79
Perbal B (2008) CCN3: doctor Jekyll and Mister Hyde. J Cell Commun Signal 2(1–2):3–7
Pickles M, Leask A (2007) Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK. J Cell Commun Signal 1(2):85–90
Planque N, Perbal B (2003) A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 3(1):15
Planque N, Long Li C, Saule S, Bleau AM, Perbal B (2006) Nuclear addressing provides a clue for the transforming activity of amino-truncated CCN3 proteins. J Cell Biochem 99(1):105–116
Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC (2009) CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174(5):1725–1734
Riser BL, Najmabadi F, Perbal B, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC, Peterson DR (2010) CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J Cell Commun Signal 4(1):39–50
Rittie L, Perbal B, Castellot JJ, Orringer JS, Voorhees JJ, Fisher GJ (2011) Spatial-temporal modulation of CCN proteins during wound healing in human skin in vivo. J Cell Commun Signal 5(1):69–80
Shimo T, Nakanishi T, Nishida T, Asano M, Sasaki A, Kanyama M, Kuboki T, Matsumura T, Takigawa M (2001) Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. Oncology 61(4):315–322
Shi-Wen X, Leask A, Abraham D (2008) Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 19(2):133–144
Sodek KL, Ringuette MJ, Brown TJ (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 124(9):2060–2070
Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM (2003) Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 278(13):11465–11470
Subramaniam MM, Lazar N, Navarro S, Perbal B, Llombart-Bosch A (2008) Expression of CCN3 protein in human Wilms’ tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies. Virchows Arch 452(1):33–39
Tamura I, Rosenbloom J, Macarak E, Chaqour B (2001) Regulation of Cyr61 gene expression by mechanical stretch through multiple signaling pathways. Am J Physiol Cell Physiol 281(5):C1524–C1532
Thompson K, Hamilton DW, Leask A (2010) ALK5 inhibition blocks TGFβ-induced CCN2 expression in gingival fibroblasts. J Dent Res Oct 5. [Epub ahead of print]
Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M (2004) Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 145(2):860–866, Epub 2003 Oct 30
Van Beek JP, Kennedy L, Rockel JS, Bernier SM, Leask A (2006) The induction of CCN2 by TGFbeta1 involves Ets-1. Arthritis Res Ther 8:R36
Wahab NA, Brinkman H, Mason RM (2001) Uptake and intracellular transport of the connective tissue growth factor: a potential mode of action. Biochem J 359(Pt 1):89–97
Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, Hameister H, Wilda M, Iwamura T, Beger HG, Adler G, Gress TM (1999) Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18(4):1073–1080
Wiesman KC, Wei L, Baughman C, Russo J, Gray MR, Castellot JJ (2010) CCN5, a secreted protein, localizes to the nucleus. J Cell Commun Signal 4(2):91–98, Epub 2010 Mar 18
Acknowledgements
Our work is supported by grants from the Canadian Institutes of Health Research to the Canadian Foundation for Innovation. A.L is a New Investigator of the Arthritis Society (Scleroderma Society of Ontario) and a recipient of an Early Researcher Award. WS is the recipient of a postdoctoral fellowship from the Canadian Scleroderma Research Group.